EcoDrugPlus

Calcium Channel, Voltage-Dependent, Beta 4a Subunit

Ensembl ID : ENSCCRG00000027408
Gene Symbol: CACNB4A
1 Cross references
161 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSCCRG00000001682
Gene Symbol: CACNG1A
1 Cross references
193 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 1a

Ensembl ID : ENSCCRG00000056690
Gene Symbol: CACNG1A
1 Cross references
193 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 2a

Ensembl ID : ENSCCRG00000051010
Gene Symbol: CACNG2A
1 Cross references
246 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 2a

Ensembl ID : ENSCCRG00000076477
Gene Symbol: CACNG2A
1 Cross references
246 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSCCRG00000017467
Gene Symbol: CACNG4B
1 Cross references
189 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 4b

Ensembl ID : ENSCCRG00000064027
Gene Symbol: CACNG4B
1 Cross references
189 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5a

Ensembl ID : ENSCCRG00000001691
Gene Symbol: CACNG5A
1 Cross references
181 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 5a

Ensembl ID : ENSCCRG00000023516
Gene Symbol: CACNG5A
1 Cross references
181 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSCCRG00000007430
Gene Symbol: CACNG6A
1 Cross references
177 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 6a

Ensembl ID : ENSCCRG00000003313
Gene Symbol: CACNG6A
1 Cross references
178 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Gamma Subunit 7a

Ensembl ID : ENSCCRG00000007434
Gene Symbol: CACNG7A
1 Cross references
187 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).